论文部分内容阅读
目的探究EB病毒感染行人免疫球蛋白和阿糖腺苷与甲强龙联合治疗对患者症状改善及病毒转阴的影响。方法 90例EB病毒感染患者,根据治疗方案不同分成对照组(38例)和观察组(52例)。对照组患者行阿糖腺苷与甲强龙联合治疗,观察组患者在对照组基础上联合人免疫球蛋白治疗,对比两组症状改善及病毒转阴情况。结果观察组在治疗后症状总积分均降低,降低幅度显著优于对照组(P<0.05);观察组病毒转阴率高于对照组(P<0.05)。结论 EB病毒感染患者行人免疫球蛋白和阿糖腺苷与甲强龙联合治疗效果显著,值得推广。
Objective To investigate the effect of combined treatment of Epstein-Barr virus-infected pedestrian immunoglobulin and vidarabine and methylprednisolone on the improvement of symptoms and virus-negative patients. Methods Ninety patients with Epstein-Barr virus (EBV) infection were divided into control group (38 cases) and observation group (52 cases) according to different treatment regimens. Patients in the control group were treated with combination of vidarabine and methylprednisolone. Patients in the observation group were treated with the combination of human immunoglobulin on the basis of the control group, and the symptoms were improved and the incidence of virus negative conversion was compared between the two groups. Results After treatment, the total score of symptoms in the observation group decreased and the reduction rate was significantly better than that in the control group (P <0.05). The virus negative rate in the observation group was higher than that in the control group (P <0.05). Conclusions The combination therapy of penta- immunoglobulin, vidarabine and methylprednisolone in patients with Epstein-Barr virus infection is effective and worthy of promotion.